Cargando…
LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506448/ http://dx.doi.org/10.1016/j.annonc.2020.08.2244 |
| _version_ | 1783585020606152704 |
|---|---|
| author | Emens, L.A. Adams, S. Barrios, C.H. Dieras, V.C. Iwata, H. Loi, S. Rugo, H.S. Schneeweiss, A. Winer, E.P. Patel, S. Henschel, V. Swat, A. Kaul, M. Molinero, L. Chui, S.Y. Schmid, P. |
| author_facet | Emens, L.A. Adams, S. Barrios, C.H. Dieras, V.C. Iwata, H. Loi, S. Rugo, H.S. Schneeweiss, A. Winer, E.P. Patel, S. Henschel, V. Swat, A. Kaul, M. Molinero, L. Chui, S.Y. Schmid, P. |
| author_sort | Emens, L.A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7506448 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75064482020-09-23 LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer Emens, L.A. Adams, S. Barrios, C.H. Dieras, V.C. Iwata, H. Loi, S. Rugo, H.S. Schneeweiss, A. Winer, E.P. Patel, S. Henschel, V. Swat, A. Kaul, M. Molinero, L. Chui, S.Y. Schmid, P. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2020-09 2020-09-22 /pmc/articles/PMC7506448/ http://dx.doi.org/10.1016/j.annonc.2020.08.2244 Text en Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Emens, L.A. Adams, S. Barrios, C.H. Dieras, V.C. Iwata, H. Loi, S. Rugo, H.S. Schneeweiss, A. Winer, E.P. Patel, S. Henschel, V. Swat, A. Kaul, M. Molinero, L. Chui, S.Y. Schmid, P. LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer |
| title | LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer |
| title_full | LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer |
| title_fullStr | LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer |
| title_full_unstemmed | LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer |
| title_short | LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer |
| title_sort | lba16 impassion130: final os analysis from the pivotal phase iii study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506448/ http://dx.doi.org/10.1016/j.annonc.2020.08.2244 |
| work_keys_str_mv | AT emensla lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT adamss lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT barriosch lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT dierasvc lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT iwatah lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT lois lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT rugohs lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT schneeweissa lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT winerep lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT patels lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT henschelv lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT swata lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT kaulm lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT molinerol lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT chuisy lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer AT schmidp lba16impassion130finalosanalysisfromthepivotalphaseiiistudyofatezolizumabnabpaclitaxelvsplacebonabpaclitaxelinpreviouslyuntreatedlocallyadvancedormetastatictriplenegativebreastcancer |